StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Friday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Up 1.7 %

ADXS stock opened at $0.03 on Friday. The company has a market cap of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.63. The business has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.03. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.98.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.